The failed promise of the 'atypical antipsychotics'
"Leading Drugs for Psychosis Come Under New Scrutiny," trumpeted a New York Times headline on May 20, 2003. The story, written by Erica Goode, notes the "excitement" with which the "atypical antipsychotics," drugs that were supposed to offer more benefits with fewer side effects than traditional antipsychotics, were greeted (Read article.)